Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. [PDF]
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N-acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as
Eadon MT +18 more
europepmc +2 more sources
Tranexamic Acid in Dacryocystorhinostomy: A Systematic Review. [PDF]
Kollatou A +3 more
europepmc +1 more source
Effectiveness of Short-Acting Oral Antihypertensives in Asymptomatic Markedly Elevated Blood Pressure: An Inverse Probability Treatment Weighted Study. [PDF]
Chotichaipiboon S +8 more
europepmc +1 more source
Reducing the Nonindicated Use of IV Hydralazine in the Inpatient Setting. [PDF]
Kumar A, Lynch J, Baldwin J.
europepmc +1 more source
Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge. [PDF]
Goshtaseb R +4 more
europepmc +1 more source
Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells. [PDF]
Yahyapour A, Askari N, Yaghoobi MM.
europepmc +1 more source
Hydralazine-Induced Diarrhea in a Geriatric Patient: A Case Report and a Review of the Literature on Deprescribing as a Diagnostic Strategy. [PDF]
Hussain A, Sprei M, Moradi L.
europepmc +1 more source
Use of Intravenous Clevidipine in the Management of Severe Preeclampsia: A Case Report. [PDF]
Brazeal C, Shapiro A.
europepmc +1 more source
Coexistence of Orthostatic Hypotension and Refractory Hypertension in Diabetic Cardiovascular Autonomic Neuropathy: A Therapeutic Dilemma. [PDF]
Qadri Z +5 more
europepmc +1 more source
Retiform purpura in a patient with iododerma and atypical perinuclear antineutrophil cytoplasmic antibody. [PDF]
Vigil SR +4 more
europepmc +1 more source

